Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 8/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 4/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24827889 | 0.82 | CYP3A4 (0.36) | OGACYP3A4CYP2D6TSHRHSD17B10 | |
| SCHEMBL24827913 | 0.82 | CYP3A4 (0.36) | OGACYP3A4CYP2D6TSHRHSD17B10 | |
| SCHEMBL21419379 | 0.82 | OGA (0.46) | OGAALDH1A1MEN1KMT2AACACB | |
| SCHEMBL17404868 | 0.78 | CYP3A4 (0.36) | OGACYP3A4CYP2D6TSHRHSD17B10 | |
| SCHEMBL24827851 | 0.77 | HSD17B10 (0.42) | CYP3A4CYP2D6TSHRHSD17B10ALDH1A1 | |
| SCHEMBL26152349 | 0.76 | MAP3K12 (0.42) | — | |
| SCHEMBL9906408 | 0.72 | MEN1 (0.40) | OGACYP2D6TSHRALDH1A1MEN1 | |
| SCHEMBL12459039 | 0.72 | MEN1 (0.40) | OGACYP2D6ALDH1A1MEN1KMT2A | |
| SCHEMBL24827912 | 0.72 | HSD17B10 (0.39) | OGACYP3A4CYP2D6TSHRHSD17B10 | |
| SCHEMBL25936345 | 0.72 | ACACB (0.43) | OGAMEN1KMT2AACACBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542266-B1 | Substituted piperidines as BTK inhibitors | HAISCO PHARMACEUTICALS PTE. LTD. (SG) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542266-B1 | Substituted piperidines as BTK inhibitors | BTK, BLK, SYK | OGA 1689/4885CYP3A4 4146/4885CYP2D6 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.